HLTH:LSE:LSE-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 225.35

Change

-1.10 (-0.49)%

Market Cap

USD 0.65B

Volume

1.21K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.26 (-0.48%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

-1.51 (-2.40%)

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

+78.00 (+0.87%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+260.00 (+3.13%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.12 (+0.87%)

USD 652.47B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.11 (+0.65%)

USD 650.46B
0R1I:LSE NVIDIA Corp.

-29.10 (-2.58%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+3.50 (+0.18%)

USD 330.91B

ETFs Containing HLTH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.03% 84% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.03% 84% B 75% C
Trailing 12 Months  
Capital Gain 7.98% 41% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.98% 39% F 50% F
Trailing 5 Years  
Capital Gain 69.00% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.00% 78% C+ 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.49% 66% D+ 69% C-
Dividend Return 8.49% 65% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.31% 75% C 85% B
Risk Adjusted Return 102.18% 98% N/A 99% N/A
Market Capitalization 0.65B 74% C 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike